Form 4: Charles River Laboratories Executive Flavia Pease Reports Stock Transactions

Corporate Executive VP & CFO of Charles River Laboratories, Flavia Pease, reports the acquisition of 2,704 shares and the disposal of 914 shares of common stock on January 31, 2025.

Summary

• Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories, reported transactions involving the company's common stock.
• On January 31, 2025, Ms. Pease acquired 2,704 shares of common stock.
• These shares were issued following the achievement of performance goals related to performance share unit awards granted on May 27, 2022.
• On the same day, Ms. Pease also disposed of 914 shares of common stock at a price of $165.57 per share.
• Following these transactions, Ms. Pease beneficially owns 11,550 shares of Charles River Laboratories common stock.

Sentiment

Score: 5

Explanation: The document is neutral, reporting routine stock transactions by an executive. There is no indication of positive or negative sentiment.

Positives

• The acquisition of 2,704 shares indicates that performance goals were met, which is a positive sign for the company's performance.

Negatives

• The disposal of 914 shares by a key executive could be interpreted negatively by some investors, although it is a relatively small portion of her total holdings.

Risks

• Executive stock transactions can sometimes be misinterpreted by the market, potentially leading to short-term price volatility.

Management Comments

• The shares acquired were issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 27, 2022.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the holdings and trading activities of key personnel.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies like Charles River Laboratories. Companies such as Labcorp (LH) and IQVIA (IQV) also have similar filings when their executives trade company stock.
• The reporting of these transactions is mandated by the SEC to ensure transparency and prevent insider trading. The volume of shares traded by Ms. Pease is not unusual for an executive at her level.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholder sentiment, but are unlikely to significantly affect the company's operations or other stakeholders.

Key Dates

Keywords

stock transactions, insider trading, executive compensation, performance shares, Flavia Pease, Charles River Laboratories, CRL